Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015737 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
A Phase 3 study of Cutaneous Lupus Erythematosus, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT06015737 is a Phase 3 study of Cutaneous Lupus Erythematosus that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 302 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT06015737, a Phase 3 study of Cutaneous Lupus Erythematosus, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Conditions Studied
Interventions
- OTHER Placebo
- COMBINATION_PRODUCT Anifrolumab
Study Locations (20)
California
- Research Site - Covina
- Research Site - Fountain Valley
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Orange
- Research Site - Orange
- Research Site - San Francisco
Florida
- Research Site - Fort Lauderdale
- Research Site - Miami
- Research Site - Miami
- Research Site - Plantation
Arizona
- Research Site - Glendale
- Research Site - Phoenix
Colorado
- Research Site - Aurora
- Research Site - Denver
Illinois
- Research Site - Chicago
- Research Site - Chicago
Connecticut
- Research Site - New Haven
District of Columbia
- Research Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2024-06-29 |
| Est. Completion | 2027-08-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06015737
The ClinicalTrials.gov registry entry for NCT06015737 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Lupus Erythematosus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06015737 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06015737 about?
NCT06015737 is a clinical study titled "A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus". This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
What is the current status of trial NCT06015737?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 302 participants. The study started on 2024-06-29. Estimated completion is 2027-08-20.
What conditions does trial NCT06015737 study?
This clinical trial studies the following conditions: Cutaneous Lupus Erythematosus.
What interventions are being tested in trial NCT06015737?
The interventions under investigation include: Placebo (OTHER), Anifrolumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06015737?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06015737 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.